VHCP Management III, LLC
Follow13F filer, CIK 1738053, New York, NY
VHCP Management III, LLC reported $171,541,000 across 16 holdings for the quarter ended 2019-03-31, in a 13F-HR filed 2019-05-14. Its ten largest share positions make up 92.24% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-19-004908
- Period
- 2019-03-31
- Reported value
- $172M
- Holdings
- 16
- Top 10 weight
- 92.24%
- New
- 2
- Sold out
- 1
Part of the filer group Venrock Healthcare Capital Partners III, L.P.
Nimish ShahKoh Bong Y
Stakes and trades reported after 2019-03-31
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- OKUR ONKURE THERAPEUTICS INC: 13G 2,309,559 shares, 5.7% of the class, 13G filed 2026-11-20, 0001231919-26-001621Timeline
Accepted , ingested - ENTX ENTERA BIO LTD: 13G 8,861,763 shares, 5.1% of the class, 13G filed 2026-10-30, 0001738048-26-000079Timeline
Accepted , ingested - LYCA LYCIA THERAPEUTICS INC: 13G 6,850,237 shares, 11.9% of the class, 13G filed 2026-10-30, 0001738048-26-000077Timeline
Accepted , ingested - FLSC FRAZIER LIFE SCIENCES ACQ-A: 13G 700,000 shares, 9% of the class, 13G filed 2026-10-27, 0001738048-26-000075Timeline
Accepted , ingested - XFOR X4 PHARMACEUTICALS INC: 13G/A 7,644,072 shares, 7.6% of the class, 13G/A filed 2026-11-16, 0001738048-26-000100Timeline
Accepted , ingested - VOR VOR BIOPHARMA INC: 13G/A 6,443,619 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000098Timeline
Accepted , ingested - KRRO KORRO BIO INC: 13G/A 1,474,162 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000096Timeline
Accepted , ingested - JBIO JADE BIOSCIENCES INC: 13G/A 3,858,984 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000094Timeline
Accepted , ingested - HELP HELUS PHARMA INC: 13G/A 2,688,175 shares, 3.5% of the class, 13G/A filed 2026-11-16, 0001738048-26-000092Timeline
Accepted , ingested - CBIO CRESCENT BIOPHARMA INC.: 13G/A 2,228,641 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000090Timeline
Accepted , ingested - ACHV ACHIEVE LIFE SCIENCE INC: 13G/A 5,502,064 shares, 5.2% of the class, 13G/A filed 2026-11-16, 0001738048-26-000088Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| AXSMnew | +1,068,044 | $15.2M |
| LA JOLLA PHARMACEUTICAL COnew | +1,003,600 | $6.45M |
| PTGXadded | +386,147 | $4.85M |
| BELLEROPHON THERAPEUTICS INCadded | +142,857 | $93.3K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| KALVreduced | -314,301 | -$9M |
| ORCHARD THERAPEUTICS PLCreduced | -230,485 | -$4.12M |
| DBV TECHNOLOGIES S Aexited | -636,800 | -$4.09M |
| KADMON HOLDINGS INCreduced | -1,000,698 | -$2.64M |
| YUMANITY THERAPEUTICS INCreduced | -125,720 | -$158K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q1 2019
Share positions as resolved from 13F-HR 0000950123-19-004908, largest first. % of portfolio is the value over $171,541,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| KALVKALVISTA PHARMACEUTICALS INC | 970,630 | $27.8M | 16.19% | -314,301 | Timeline | ||
| TRICIDA INCTRICIDA INC | 650,585 | $25.1M | 14.65% | 0 | |||
| BCRXBIOCRYST PHARMACEUTICALS INC | 3,061,091 | $24.9M | 14.53% | 0 | Timeline | ||
| AXSMAXSOME THERAPEUTICS INC. | 1,068,044 | $15.2M | 8.86% | new | Timeline | ||
| ObsEva SAObsEva SA | 1,159,789 | $14.8M | 8.65% | 0 | |||
| ORCHARD THERAPEUTICS PLCORCHARD THERAPEUTICS PLC | 811,030 | $14.5M | 8.45% | -230,485 | |||
| RA PHARMACEUTICALS INCRA PHARMACEUTICALS INC | 594,713 | $13.3M | 7.77% | 0 | |||
| PTGXPROTAGONIST THERAPEUTICS INC | 809,323 | $10.2M | 5.93% | +386,147 | Timeline | ||
| LA JOLLA PHARMACEUTICAL COLA JOLLA PHARMACEUTICAL CO | 1,003,600 | $6.45M | 3.76% | new | |||
| KINIKSA PHARMACEUTICALS LTDKINIKSA PHARMACEUTICALS LTD | 327,777 | $5.92M | 3.45% | 0 | |||
| MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INC | 1,258,964 | $5.26M | 3.07% | 0 | |||
| KADMON HOLDINGS INCKADMON HOLDINGS INC | 1,387,874 | $3.66M | 2.14% | -1,000,698 | |||
| BELLEROPHON THERAPEUTICS INCBELLEROPHON THERAPEUTICS INC | 2,417,227 | $1.58M | 0.92% | +142,857 | |||
| GEMPHIRE THERAPEUTICS INCGEMPHIRE THERAPEUTICS INC | 869,538 | $1M | 0.58% | 0 | |||
| YUMANITY THERAPEUTICS INCYUMANITY THERAPEUTICS INC | 722,890 | $911K | 0.53% | -125,720 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 66,667 | $903K | 0.53% | 0 |
Sold out in Q1 2019
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| DBV TECHNOLOGIES S ADBV TECHNOLOGIES S A | 636,800 | $4.09M | shares |
How Q1 2019 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-19-004908 | base | 2019-05-14 | acceptance time not in the bulk data set |